Exact Mass: 481.081602
Exact Mass Matches: 481.081602
Found 85 metabolites which its exact mass value is equals to given mass value 481.081602
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Yersiniabactin
C21H27N3O4S3 (481.1163622000001)
A member of the class of thiazolidines that is (4S)-4-methyl-4,5-dihydro-1,3-thiazole-4-carboxylic acid which is substituted at position 2 by a (1S)-1-hydroxy-1-{(4R)-2-[(4R)-2-(2-hydroxyphenyl)-4,5-dihydro-1,3-thiazol-4-yl]-1,3-thiazolidin-4-yl}-2-methylpropan-2-yl group. A siderophore found in the gram-negative bacterium species, Yersinia enterocolitica and Yersinia pestis. D064449 - Sequestering Agents > D002614 - Chelating Agents > D007502 - Iron Chelating Agents
Talampicillin
C24H23N3O6S (481.13074980000005)
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01C - Beta-lactam antibacterials, penicillins > J01CA - Penicillins with extended spectrum D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic Same as: D08557
N-(2,2,2-Trifluoroethyl)-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}benzenesulfonamide
C17H12F9NO3S (481.0394150000001)
T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα[1]. T0901317 activates FXR with an EC50 of 5 μM[2]. T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively[3]. T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice[4][5].
T0901317
C17H12F9NO3S (481.0394150000001)
T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα[1]. T0901317 activates FXR with an EC50 of 5 μM[2]. T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively[3]. T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice[4][5].
6-(Methylsulfonyl)hexyl glucosinolate
6-(Methylsulfonyl)hexyl glucosinolate is present in crucifers. Present in crucifers
Talampicillin
C24H23N3O6S (481.13074980000005)
Yersiniabactin
C21H27N3O4S3 (481.1163622000001)
Glucomalcomiin
Acquisition and generation of the data is financially supported by the Max-Planck-Society
2-(4-Methoxyphenyl)-2,2-dimethylethyl glucosinolate
C18H27NO10S2 (481.10763219999995)
6-Hydroxydelphinidin 3-glucoside
4-(3-Chloro-2-cyanophenoxy)-N-[4-(2-methyl-1,3-thiazol-4-yl)phenyl]benzenesulfonamide
C23H16ClN3O3S2 (481.03215760000006)
Cys Cys Glu Gln
C16H27N5O8S2 (481.13009819999996)
Cys Cys Gln Glu
C16H27N5O8S2 (481.13009819999996)
Cys Asp Met Asn
C16H27N5O8S2 (481.13009819999996)
Cys Asp Asn Met
C16H27N5O8S2 (481.13009819999996)
Cys Glu Cys Gln
C16H27N5O8S2 (481.13009819999996)
Cys Glu Gln Cys
C16H27N5O8S2 (481.13009819999996)
Cys Met Asp Asn
C16H27N5O8S2 (481.13009819999996)
Cys Met Asn Asp
C16H27N5O8S2 (481.13009819999996)
Cys Asn Asp Met
C16H27N5O8S2 (481.13009819999996)
Cys Asn Met Asp
C16H27N5O8S2 (481.13009819999996)
Cys Gln Cys Glu
C16H27N5O8S2 (481.13009819999996)
Cys Gln Glu Cys
C16H27N5O8S2 (481.13009819999996)
Asp Cys Met Asn
C16H27N5O8S2 (481.13009819999996)
Asp Cys Asn Met
C16H27N5O8S2 (481.13009819999996)
Asp Met Cys Asn
C16H27N5O8S2 (481.13009819999996)
Asp Met Asn Cys
C16H27N5O8S2 (481.13009819999996)
Asp Asn Cys Met
C16H27N5O8S2 (481.13009819999996)
Asp Asn Met Cys
C16H27N5O8S2 (481.13009819999996)
Glu Cys Cys Gln
C16H27N5O8S2 (481.13009819999996)
Glu Cys Gln Cys
C16H27N5O8S2 (481.13009819999996)
Glu Gln Cys Cys
C16H27N5O8S2 (481.13009819999996)
Met Cys Asp Asn
C16H27N5O8S2 (481.13009819999996)
Met Cys Asn Asp
C16H27N5O8S2 (481.13009819999996)
Met Asp Cys Asn
C16H27N5O8S2 (481.13009819999996)
Met Asp Asn Cys
C16H27N5O8S2 (481.13009819999996)
Met Asn Cys Asp
C16H27N5O8S2 (481.13009819999996)
Met Asn Asp Cys
C16H27N5O8S2 (481.13009819999996)
Asn Cys Asp Met
C16H27N5O8S2 (481.13009819999996)
Asn Cys Met Asp
C16H27N5O8S2 (481.13009819999996)
Asn Asp Cys Met
C16H27N5O8S2 (481.13009819999996)
Asn Asp Met Cys
C16H27N5O8S2 (481.13009819999996)
Asn Met Cys Asp
C16H27N5O8S2 (481.13009819999996)
Asn Met Asp Cys
C16H27N5O8S2 (481.13009819999996)
Gln Cys Cys Glu
C16H27N5O8S2 (481.13009819999996)
Gln Cys Glu Cys
C16H27N5O8S2 (481.13009819999996)
Gln Glu Cys Cys
C16H27N5O8S2 (481.13009819999996)
6-(Methylsulfonyl)hexyl glucosinolate
silybin (mixture of silybin a and silybin b)
C25H21O10 (481.11346660000004)
1H-Pyrrolo[2,3-b]pyridine, 1-[(4-Methylphenyl)sulfonyl]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(2-thiazolyl)-
Diethyl thiophosphoryl-(Z)-2-(2-aminothiazol-4-yl)-2-(tert-butoxycarbonyl)isopropoxyiminoacetate
C17H28N3O7PS2 (481.11062280000004)
1-Biotinylamino-3,6,9-trioxaundecane-11-bromide
C18H32BrN3O5S (481.12459220000005)
4-METHYLUMBELLIFERYL-2-ACETAMIDO-2-DEOXY-6-SULPHATE-β-D-GLUCOPYRANOSIDE
Imidazol-3-ide;2-pyridin-2-ylpyridine;ruthenium(3+)
Enloplatin [mart.]
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent C274 - Antineoplastic Agent > C798 - Radiosensitizing Agent > C1450 - Platinum Compound
3-Amino-4-hydroxybenzoate-adenylate
C17H18N6O9P- (481.0872848000001)
N-[1-[(4-bromoanilino)-oxomethyl]cyclohexyl]-N-(2-furanylmethyl)-2-pyridinecarboxamide
4-[[1-[(3,4-Dichlorophenyl)methyl]-3-indolyl]-(3-methyl-5-oxo-1,2-dihydropyrazol-4-yl)methyl]-5-methyl-1,2-dihydropyrazol-3-one
3-(1,3-benzodioxol-5-ylmethyl)-7-[1,4-dioxa-8-azaspiro[4.5]decan-8-yl(oxo)methyl]-2-sulfanylidene-1H-quinazolin-4-one
C24H23N3O6S (481.13074980000005)
N-[3-[(2,4-dimethylphenyl)sulfamoyl]-4-methylphenyl]-3-oxo-4H-1,4-benzothiazine-6-carboxamide
C24H23N3O4S2 (481.11299180000003)
N-(3-cyano-6-methyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-phenyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-2-carboxamide
5-bromo-2-methoxy-3-methyl-N-[4-(4-methylsulfonyl-1-piperazinyl)phenyl]benzamide
C20H24BrN3O4S (481.06708040000007)
Ethyl 4,5-dimethyl-2-[[2-(6-methyl-4-oxo-5-phenylthieno[2,3-d]pyrimidin-3-yl)acetyl]amino]thiophene-3-carboxylate
C24H23N3O4S2 (481.11299180000003)
N-[[3-bromo-4-[(4-fluorophenyl)methoxy]-5-methoxyphenyl]methyl]-2-[(1-methyl-5-tetrazolyl)thio]ethanamine
C19H21BrFN5O2S (481.05832780000003)
(3-oxo-1H-2-benzofuran-1-yl) (2S,5S,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
C24H23N3O6S (481.13074980000005)
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 2-methoxybenzoate
C18H20N5O9P (481.0998600000001)
AGI-6780
C21H18F3N3O3S2 (481.07416340000003)
AGI-6780 that potently and selectively inhibits the tumor-associated mutant IDH2R140Q with IC50 of 23±1.7 nM. AGI-6780 is less potent against IDH2WT with IC50 of 190±8.1 nM.
SB-399885 hydrochloride
C18H22Cl3N3O4S (481.0396542000001)
SB-399885 hydrochloride is a 5-HT6 receptor antagonist.
UC2288
C20H18ClF6N3O2 (481.09916699999997)
UC2288 is a novel, cell-permeable, and orally active p21 attenuator (relatively selective activity for p21), which is synthesized based Sorafenib (HY-10201). UC2288 decreases p21 mRNA expression independently of p53, and attenuates p21 protein levels with minimal effect on p21 protein stability. UC2288 has no inhibition of VEGFR2 and Raf kinases even at 10 μM[1].